The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
RGD and other bioactive ligands can be presented on the surface of a biomaterial in a number of different spatial arrangements, and it has been demonstrated that these arrangements have a significant impact on cell behavior. In self-assembled monolayers, it was found that adhesion and proliferation of both human umbilical vein endothelial cells (HUVECs) and human mesenchymal stem cells (MSCs) increased as a function of RGD peptide density. These studies also showed that RGD density could change integrin expression, which has been postulated to enable control of biochemical signaling pathways. Further investigation of MSCs on self-assembled monolayers showed that modulating RGD density and the affinity of RGD for αvβ3 (through use of linear and cyclized RGD) could be used to control the differentiation of MSCs. The effect of RGD presentation on cells in 3D biomaterials, which more accurately replicate the in vivo environment, has also been evaluated. In degradable polyethylene glycol hydrogels, the length of capillary-like structures formed by HUVECs was directly proportional to the density of RGD in the hydrogel. Additionally, studies in nano-patterning have shown that, whereas an increase in global RGD density increases cell adhesion strength until saturation, an increase in local (mico/nano-scale) RGD density does not follow this trend.
=== Chemical === Neptunium has five ionic oxidation states ranging from +3 to +7 when forming chemical compounds, which can be simultaneously observed in solutions. It is the heaviest actinide that can lose all its valence electrons in a stable compound. The most stable state in solution is +5, but the valence +4 is preferred in solid neptunium compounds. Neptunium metal is very reactive. Ions of neptunium are prone to hydrolysis and formation of coordination compounds.
1921 Research on the role of pancreas in the nutritive assimilation 1922 Frederick Banting, Charles Best and James Collip use bovine insulin extract in humans at Connaught Laboratories in Toronto, Canada. 1922 Leonard Thompson becomes the first human to be treated with insulin. 1922 James D. Havens, son of former congressman James S. Havens, becomes the first American to be treated with insulin. 1922 Elizabeth Hughes Gossett, daughter of the US Secretary of State, becomes the first American to be (officially) treated in Toronto. 1923 Dr. Trent Champion de Crespigny delivers the first treatments with insulin produced in Australia, to a 9-year-old, in Adelaide, South Australia, on 7 January 1923. 1923 Eli Lilly produces commercial quantities of much purer bovine insulin than Banting et al. had used 1923 Farbwerke Hoechst, one of the forerunners of today's Sanofi Aventis, produces commercial quantities of bovine insulin in Germany 1923 Hans Christian Hagedorn founds the Nordisk Insulinlaboratorium in Denmark – forerunner of today's Novo Nordisk 1923 Constance Collier returns to health after being successfully treated with insulin in Strasbourg 1924 Margaret Cheadle, a research biochemist in the laboratory of T. Brailsford Robertson at the University of Adelaide, determined that approx. 167 "mouse units" of insulin were "equivalent to one two-kilogram rabbit-unit". 1926 Nordisk receives a Danish charter to produce insulin as a non-profit 1936 Canadians David M. Scott and Albert M.
=== Reports by the Western media === On 9 August 2008, the Associated Press reported that one Russian conscript said he was suddenly deployed to South Ossetia instead of expected exercises in North Ossetia. On 18 August 2008, Le Figaro published the report by journalist who was told by a young Russian soldier at some checkpoint in Georgia that he came from Shali, Chechen Republic and that they left on 5 August 2008. On 27 August 2008, the Financial Times quoted an unnamed Russian colonel as saying: "We were called to react to alarm on the night of 7th. [...] There was such an escalation of events that I cannot remember exactly when we entered the tunnel." On 29 August 2008, journalist Robert Parsons wrote in The Guardian that Russian servicemen deployed in Georgia had told him that they had been preparing for the war for weeks. In September 2008, The New York Times quoted anonymous American official as having stated that the western intelligence had information that two battalions of the 135th Regiment could have entered South Ossetia on the night of August 7. In May 2009, the United States Department of State official Matthew Bryza told Echo of Moscow that the United States knew that the Russian tank deployments to South Ossetia began in 2005 and these weaponry were used in August 2008 invasion. He confirmed that Russian tanks were entering South Ossetia before 7 August 2008, but he could not say the exact number of incoming Russian tanks on 7 August.
Sources: en.wikipedia.org
7-Acetoxymitragynine is an opioid drug which is a semi-synthetic derivative of 7-hydroxymitragynine, a natural product derived from the South-East Asian tree known as kratom. It can be derived by acetylation of the hydroxyl group of 7-hydroxymitragynine, for instance with acetic anhydride, but can also be produced directly from mitragynine by reaction with Lead(IV) acetate. Unlike heroin, 7-acetoxymitragynine is less potent than 7-hydroxymitragynine, but nevertheless retains opioid activity. However It is not commonly or specifically found nor sold.
== External links == Official website Historic American Engineering Record (HAER) No. AL-188, "Atlantic Ice and Coal Company, 135 Prince Street, Montgomery, Montgomery County, AL", 23 photos, 14 measured drawings, 37 data pages, 2 photo caption pages Business data for Americold Realty Trust, Inc.:
=== Space age swimsuit === Langley Research Center's wind tunnel testing facilities and fluid flow analysis software supported Speedo's design of a space age-enriched swimsuit. The resulting LZR Racer reduced skin friction drag 24% more than the previous Speedo swimsuit. In March 2008, athletes wearing the LZR Racer broke 13 swimming world records.
Sprigg urged Letsie I to negotiate Masopha's unconditional surrender, until a force of Cape Mounted Riflemen (CMR) could arrive to assist him. Letsie I replied that this was unrealistic, as most of the Basuto, including his sons, had rallied behind Masopha. Letsie and his armed retinue, returned to their village on 19 August after several days of negotiations, fearing that they would be ambushed if they remained outside Thaba Bosiu any longer. In a last ditch effort to prevent an uprising, Sprigg visited Letsie I in person. Letsie I then held another pitso—under Sprigg's new terms the rebel chiefs were to appear in court where they would receive a token fine, pledge to compensate those whose property they had seized, and comply with the gun regulations. Masopha remained defiant and held an assembly of his own, where he and Lerotholi began to prepare for war. Masopha believed that the Cape's troops had proved themselves to be incompetent during the suppression of Moorosi's revolt. He was further encouraged by rumors that the British would refuse to reinforce the Cape, and by the British defeat at the Battle of Isandlwana a year prior.
=== Anraj Chabra === Anraj Chabra (Irfan Shamji) is a mild-mannered junior trader at Pierpoint working under Rishi, who frequently takes his anger out on him. Rishi uses Anraj's account to run a £300 million long on pound sterling against the US dollar, raising major flags at Pierpoint's risk management division (and jeopardizing Anraj's job and FCA license) until Rishi miraculously nets £18 million from the investment due to a last-minute tax cut by the UK government. Rishi also steals some of Anraj's money (claiming he is using it to bet on horse races) to gamble away at a casino. Anraj later admits that he is afraid to come to work because of Rishi's volatile behavior. Anraj and Sweetpea become friends over the course of their time at Pierpoint, in part due to their mutual frustration with Rishi. Anraj is briefly seen in series 4 attending the ALPHA conference, where Harper publicizes her findings on the fraudulent profits of fintech company Tender; he and Eric exchange a friendly glance.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.